Insider Cluster (4 insiders) ·Filed May 21, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
NEUTRAL
Impact 4/10
Horizondays Processed4mo ago
Insider cluster: 2 insiders, $40.2M total
Actionable Insight • Neutral

Insider sales post-acquisition close are likely profit-taking, not a fundamental signal. Monitor for additional filings; the next 10-Q will update on deal integration. No immediate trading action warranted.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
NBIX ▼ -1.45% at T+60d
NEUTRAL call ✗ call lost -1.45% · α vs SPY -4.37% · entry $156.50 → $154.23
Entry anchored
May 21, 2026
via day open
T+1d
-0.50%
call -0.50% · α -1.08%
$155.72
settled 4mo ago
T+5d
+2.54%
call +2.54% · α +0.89%
$160.48
settled 4mo ago
T+20d
+3.27%
call +3.27% · α +3.44%
$161.62
settled 3mo ago
T+60d
-1.45%
call -1.45% · α -4.37%
$154.23
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Two directors sold $40.2M in NBIX shares ($2.36M and $37.82M) within days of Neurocrine's $2.9B acquisition of Soleno Therapeutics closing on May 18, 2026. The sales represent 0.26% of market cap and follow option exercises by the same insiders, indicating routine profit-taking post-deal rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$40.2M
Insiders
4

Key Facts

  • Directors Richard F. Pops and Kevin Charles Gorman sold a combined $40.2M in open-market sales on May 15 and May 19, 2026.
  • Sales occurred after the close of Neurocrine's $2.9B acquisition of Soleno Therapeutics on May 18, 2026.
  • The total sale value is 0.26% of NBIX's $15.6B market cap, a modest amount.
  • Both insiders also exercised stock options around the same dates, converting non-cash awards into shares sold.

Financial Impact

$40.2M in insider sales, 0.26% of market cap

dilutioninsider ownership

Risk Factors

  • Further insider selling could appear, but at current magnitude it is not material.
  • Integration of Soleno's VYKAT XR may face commercial hurdles not yet reflected in insider behavior.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (35 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NBIX-1779405695847
17 reports for NBIX
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +27.40%Apr 6, 2026
Filters
Rows
Reports for NBIX — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 3/10
$149.50 $139.49▼ −6.70%▼ −9.26%$143.18 (−4.23%)
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$174.10 $170.88▼ −1.85%▼ −1.06%$143.18 (−17.76%)
Jul 9, 2026
12w ago
Press Release
NEUTRAL ★ 2/10
$177.11 $171.55▼ −3.14%▼ −2.58%$143.18 (−19.16%)
Jun 9, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$160.86 $156.42▼ −2.76%▼ −6.19%$143.18 (−10.99%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$165.24 $159.51▼ −3.47%▼ −5.88%$143.18 (−13.35%)
Jun 8, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$165.24 $159.51▼ −3.47%▼ −5.88%$143.18 (−13.35%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$163.88 $159.76▼ −2.51%▼ −3.08%$143.18 (−12.63%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$164.23 $160.86▼ −2.05%▲ +1.77%$143.18 (−12.81%)
Showing 10 of 17

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 21, 2026